{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:29:02Z","timestamp":1793395742271,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s13555-024-01126-y","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T17:14:55Z","timestamp":1709831695000},"page":"767-775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4497-8487","authenticated-orcid":false,"given":"Tom M.","family":"Hillary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6269-6354","authenticated-orcid":false,"given":"Tine","family":"Vanhoutvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miet","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-9831","authenticated-orcid":false,"given":"Maya","family":"Imbrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-8918","authenticated-orcid":false,"given":"Thomas","family":"Vanassche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-5038","authenticated-orcid":false,"given":"Marjan","family":"Garmyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-3019","authenticated-orcid":false,"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"issue":"1","key":"1126_CR1","first-page":"23","volume":"4","author":"HA Alshobaili","year":"2010","unstructured":"Alshobaili HA, Shahzad M, Al-Marshood A, Khalil A, Settin A, Barrimah I. Genetic background of psoriasis. Int J Health Sci (Qassim). 2010;4(1):23\u20139.","journal-title":"Int J Health Sci (Qassim)"},{"issue":"4","key":"1126_CR2","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840\u20138.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1126_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjd.14528","volume":"175","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016;175(3):487\u201392.","journal-title":"Br J Dermatol"},{"key":"1126_CR4","first-page":"1","volume":"12","author":"A Al-Janabi","year":"2022","unstructured":"Al-Janabi A, Yiu ZZN. Biologics in psoriasis: updated perspectives on long-term safety and risk management. Psoriasis (Auckl). 2022;12:1\u201314.","journal-title":"Psoriasis (Auckl)"},{"issue":"Suppl 2","key":"1126_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","volume":"26","author":"K Reich","year":"2012","unstructured":"Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):3\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1126_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2340\/00015555-0770","volume":"90","author":"M Augustin","year":"2010","unstructured":"Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147\u201351.","journal-title":"Acta Derm Venereol"},{"issue":"Suppl 2","key":"1126_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2133.2008.08780.x","volume":"159","author":"F Sp\u00e4h","year":"2008","unstructured":"Sp\u00e4h F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008;159(Suppl 2):10\u20137.","journal-title":"Br J Dermatol"},{"issue":"14","key":"1126_CR8","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735\u201341.","journal-title":"JAMA"},{"issue":"4","key":"1126_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","volume":"20","author":"WH Boehncke","year":"2011","unstructured":"Boehncke WH, Boehncke S, Tobin AM, Kirby B. The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303\u20137.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1126_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamadermatol.2021.4918","volume":"158","author":"T-L Chen","year":"2022","unstructured":"Chen T-L, Lee L-L, Huang H-K, et al. Association of psoriasis with incident venous thromboembolism and peripheral vascular disease: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(1):59\u201367.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1126_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018125","volume":"6","author":"O Ahlehoff","year":"2011","unstructured":"Ahlehoff O, Gislason GH, Lindhardsen J, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS ONE. 2011;6(3): e18125.","journal-title":"PLoS ONE"},{"issue":"39","key":"1126_CR12","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","volume":"39","author":"A Ogdie","year":"2018","unstructured":"Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39(39):3608\u201314.","journal-title":"Eur Heart J"},{"issue":"1","key":"1126_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/07853890.2021.1942974","volume":"53","author":"T Hillary","year":"2021","unstructured":"Hillary T, Clijmans J, Vermeire S, et al. Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis. Ann Med. 2021;53(1):1074\u201381.","journal-title":"Ann Med"},{"issue":"8","key":"1126_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","volume":"12","author":"JA Heit","year":"2015","unstructured":"Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464\u201374.","journal-title":"Nat Rev Cardiol"},{"issue":"23 Suppl 1","key":"1126_CR15","first-page":"I4","volume":"107","author":"RH White","year":"2003","unstructured":"White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4-8.","journal-title":"Circulation"},{"key":"1126_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.thromres.2015.11.033","volume":"137","author":"SD Grosse","year":"2016","unstructured":"Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3\u201310.","journal-title":"Thromb Res"},{"issue":"1","key":"1126_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1179\/acb.2002.004","volume":"57","author":"L Annemans","year":"2002","unstructured":"Annemans L, Robays H, Bruart J, Verstraeten P. Variation in medical resource utilisation in the management of pulmonary embolism in Belgium. Acta Clin Belg. 2002;57(1):11\u20138.","journal-title":"Acta Clin Belg"},{"issue":"3","key":"1126_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.semarthrit.2021.04.008","volume":"51","author":"AC Damian","year":"2021","unstructured":"Damian AC, Colaco K, Rohekar S, et al. The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Semin Arthritis Rheum. 2021;51(3):547\u201352.","journal-title":"Semin Arthritis Rheum"},{"key":"1126_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ced\/llad292","volume":"49","author":"T Hillary","year":"2023","unstructured":"Hillary T, Grymonprez M, Vanhooren E, G\u00fcven\u00e7 C, Garmyn M, Vermeire S. Venous thromboembolism in psoriasis patients: a retrospective monocentric chart review on an overlooked comorbidity. Clin Exp Dermatol. 2023;49:75\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"1126_CR20","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1172\/JCI60229","volume":"122","author":"N Mackman","year":"2012","unstructured":"Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012;122(7):2331\u20136.","journal-title":"J Clin Invest"},{"issue":"11","key":"1126_CR21","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2174\/138161212799504731","volume":"18","author":"K Aksu","year":"2012","unstructured":"Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012;18(11):1478\u201393.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"1126_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/blood-2004-08-3253","volume":"105","author":"T Lisman","year":"2005","unstructured":"Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3):1102\u20135.","journal-title":"Blood"},{"issue":"3","key":"1126_CR23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/MIB.0000000000000301","volume":"21","author":"L Bollen","year":"2015","unstructured":"Bollen L, VandeCasteele N, Peeters M, et al. Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2015;21(3):570\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"1126_CR24","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","volume":"139","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Reich K, Tha\u00e7i D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054\u201362.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1126_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721\u20138.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1126_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jid.2017.09.021","volume":"138","author":"Y Li","year":"2018","unstructured":"Li Y, Golden JB, Camhi MI, et al. Protection from psoriasis-related thrombosis after inhibition of IL-23 or IL-17A. J Invest Dermatol. 2018;138(2):310\u20135.","journal-title":"J Invest Dermatol"},{"key":"1126_CR27","unstructured":"(FDA) USFaDA. 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death#:~:text=FDA%20is%20requiring%20new%20and,%2C%20and%20Rinvoq%20(upadacitinib). Accessed 01 Dec 2023."},{"key":"1126_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.trsl.2019.08.009","volume":"215","author":"F Posch","year":"2020","unstructured":"Posch F, Hofer S, Thaler J, et al. Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Transl Res. 2020;215:41\u201356.","journal-title":"Transl Res"},{"issue":"12","key":"1126_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051447","volume":"7","author":"L Traby","year":"2012","unstructured":"Traby L, Kollars M, Eischer L, Eichinger S, Kyrle PA. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS ONE. 2012;7(12): e51447.","journal-title":"PLoS ONE"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01126-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01126-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01126-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T16:18:42Z","timestamp":1711469922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01126-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01126-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"12 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tom Hillary has received consultancy from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo Pharma, Eli Lilly, Novartis, Sandoz, UCB Pharma; speaker fees from AbbVie, Almirall, Amgen, Biogen, Celgene, Janssen, Leo Pharma, Eli Lilly, Novartis, Sanofi, UCB Pharma; research funding from AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Novartis, UCB Pharma. SV Has received grants from: AbbVie, J&J, Pfizer, Galapagos, Takeda and Has received consulting and\/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma. Tine Vanhoutvin, Miet Peeters, Maya Imbrechts, ThomasVanassche and Marjan Garmyn have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional Board Approval (s62301) was obtained prior to the start of this project; prior to enrolment, all patients signed informed consent. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}